- Home
- CLLS vs KIO Comparison
CLLS vs KIO Comparison
Compare CLLS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | KIO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 461.1M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CLLS | KIO |
|---|---|---|
| Price | $3.22 | $11.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 32.4K | ★ 140.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $10.65 |
| 52 Week High | $5.48 | $12.83 |
Technical Indicators
Market Signals| Indicator | CLLS | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 45.21 |
| Support Level | $3.05 | $10.66 |
| Resistance Level | $3.83 | $11.25 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 24.19 | 35.37 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.